BOLT
What one share of Bolt Biotherapeutics holds
Pharmaceutical Preparations
Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs.
Bolt Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.68 |
|---|---|
| Profit | −$16.38 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$17.98 |
| Cash and investments | $6.68 |
| Book value | $6.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.20 | −$577.72 | $31.03 | −$481.09 | — | −$985.35 |
| 2021 | $0.76 | −$59.40 | $1.41 | −$35.79 | — | $133.75 |
| 2022 | $3.07 | −$47.16 | $1.05 | −$42.00 | — | $90.75 |
| 2023 | $4.17 | −$36.60 | $0.11 | −$36.88 | — | $59.16 |
| 2024 | $4.03 | −$33.06 | $0.02 | −$32.12 | — | $29.84 |
| 2025 | $4.12 | −$17.85 | $0.04 | −$21.35 | — | $13.80 |